Volume 5.49 | Dec 12

Mammary Cell News 5.49 December 12, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program
Researchers developed three-dimensional organoid assays to identify the most invasive cancer cells in primary breast tumors. Collective invasion was led by specialized cancer cells that were defined by their expression of basal epithelial genes, such as cytokeratin-14 and p63. [Cell]
Abstract | Full Article | Graphical Abstract
Dissociation Enzymes For Optimized Human Mammary Tissue Dissociation and Culture - FREE Protocols
PUBLICATIONS (Ranked by impact factor of the journal)

MYC-Driven Accumulation of 2-Hydroxyglutarate Is Associated with Breast Cancer Prognosis
Researchers characterized the metabolomic profile of human breast tumors and uncovered intrinsic metabolite signatures in these tumors using an untargeted discovery approach and validation of key metabolites. The oncometabolite 2-hydroxyglutarate accumulated at high levels in a subset of tumors and human breast cancer cell lines. [J Cell Invest] Full Article

Hypoxia-Inducible Factors Mediate Coordinated RhoA-ROCK1 Expression and Signaling in Breast Cancer Cells
Scientists report that hypoxia-inducible factors coordinately activate RhoA and Rho kinase 1 (ROCK1) expression and signaling in breast cancer cells, leading to cell and matrix contraction, focal adhesion formation, and motility through phosphorylation of myosin light chain and focal adhesion kinase. [Proc Natl Acad Sci USA] Abstract

A Critical Role of CD29 and CD49f in Mediating Metastasis for Cancer-Initiating Cells Isolated from a Brca1-Associated Mouse Model of Breast Cancer
Scientists investigated metastatic potential of cancer stem cells (CSCs) isolated from mammary tumors of a Brca1-mutant mouse model. They indicated that CSCs, which are enriched in CD24+CD29+/CD49f+ cell population, displayed much higher migration ability than CD24CD29/CD49f cells in tissue culture and enhanced metastatic potential in allograft-nude mice. [Oncogene] Abstract

Contribution of an Alveolar Cell of Origin to the High-Grade Malignant Phenotype of Pregnancy-Associated Breast Cancer
By generating a WAP-tva transgenic line for expression of ErbB2 selectively in WAP+ mammary alveolar cells, scientists found that tumors had similar morphological phenotypes (high grade, poorly differentiated, stroma-rich and estrogen receptor-negative), irrespective of the time since pregnancy and even in the absence of pregnancy. [Oncogene] Abstract

Rb Suppresses Collective Invasion, Circulation and Metastasis of Breast Cancer Cells in CD44-Dependent Manner
Researchers showed that retinoblastoma (Rb) acts as a key suppressor of multiple stages of metastatic progression. Rb suppresses collective cell migration and CD44-dependent formation of F-actin positive protrusions in vitro and cell-cluster based lymphovascular invasion in vivo. [PLoS One] Full Article

Epidermal Growth-Factor – Induced Transcript Isoform Variation Drives Mammary Cell Migration
Signal-induced transcript isoform variation (TIV) includes alternative promoter usage as well as alternative splicing and alternative polyadenylation of mRNA. To assess the phenotypic relevance of signal-induced TIV, researchers employed exon arrays and breast epithelial cells, which migrate in response to the epidermal growth factor. [PLoS One] Full Article

Influence of Terminal Differentiation and PACAP on the Cytokine, Chemokine, and Growth Factor Secretion of Mammary Epithelial Cells
Differentiation was hormonally induced by lactogenic hormones in confluent cultures of HC11 mouse mammary epithelial cells. Researchers investigated the effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on mammary cell differentiation as well as release of cytokines, chemokines, and growth factors. [J Mol Neurosci] Abstract

Identification and Quantification of the Main Active Anticancer Alkaloids from the Root of Glaucium flavum
In vitro evaluation of growth inhibitory activity on breast cancer and normal cells demonstrated that purified protopine did not reproduce the full cytotoxic activity of the alkaloid root extract on cancer cell lines. [Int J Mol Sci] Abstract | Full Article


Axillary Lymph Node Dissection Versus No Dissection in Patients with T1N0 Breast Cancer: A Randomized Clinical Trial (INT09/98)
The authors conducted a single-center randomized trial (INT09/98) to determine the impact of avoiding axillary surgery in patients with T1N0 breast cancer and planning chemotherapy based on biological factors of the primary tumor on long-term disease control. [Cancer] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
Role of Sphingolipids in Estrogen Signaling in Breast Cancer Cells: An Update
The authors summarize novel experimental evidence linking sphingolipids to estrogen-activated effects, highlight the role of sphingolipids in cancer cells, and discuss new avenues for future estrogen and sphingolipid signalling cross-road research. [J Endocrinol] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Calithera Biosciences Presents Data for CB-839 in Triple-Negative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium
Calithera Biosciences announced the presentation of preclinical data for its lead anti-cancer therapeutic candidate, CB-839. [Press release from Calithera Biosciences discussing research presented at the 2013 San Antonio Breast Cancer Symposium, San Antonio] Press Release

Biomarker Linked to Aggressive Breast Cancers, Poor Outcomes in African-Americans
Among African-American women with breast cancer, increased levels of the protein HSET were associated with worse breast cancer outcomes, according to results. [American Association for Cancer Research]
Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
Verastem Initiates Clinical Trial of Dual mTOR/PI3K Inhibitor
Verastem, Inc. announced the initiation of a Phase I trial of VS-5584, a dual mTORC1/2 and PI3K inhibitor, in patients with advanced solid tumors or lymphoma. VS-5584 decreased cancer stem cells across multiple in vitro and in vivo cancer models including triple negative breast cancer, small cell lung cancer and ovarian cancer. [Verastem, Inc.] Press Release

Bayer HealthCare Announces Collaboration with the University of Texas MD Anderson Cancer Center
Bayer HealthCare announced that the company has signed a master agreement for the performance of clinical trials with the Houston-based University of Texas MD Anderson Cancer Center. The growing oncology franchise of Bayer HealthCare explores specific treatment approaches for various tumors, including such common types of cancer as prostate, colorectal and breast cancer, as well as rarer forms like kidney, liver and thyroid cancer. [PR Newswire Association LLC] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Molecular Medicine Tri-Conference 2014
February 9-14, 2014
San Francisco, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Associate – Breast Cancer Development (University of Pittsburgh Cancer Institute)

NEW Postdoctoral Scholar – Breast Cancer Research (Northwestern University)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

PhD Position – Integrated Classification of Breast Cancers to Optimize Treatment Protocols (Radboud University Nijmegen Medical Centre)

Assistant, Associate, or Research Professor – Breast Cancer (Indiana University School of Medicine)

Postdoctoral Fellow – Breast Cancer Stem Cell Biology (UC – College of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mammary Cell News: Archives | Events | Contact Us